Please enable JavaScript to continue using this application.

Compare $LCTX vs $PYXS | Chartloom

Compare

$LCTX vs $PYXS

Lineage Cell Therapeutics Inc · Pyxis Oncology Inc

LCTX

Lineage Cell Therapeutics Inc

PYXS

Pyxis Oncology Inc

Compare $LCTX vs $PYXS

Comparing Lineage Cell Therapeutics Inc and Pyxis Oncology Inc

LCTXLineage Cell Therapeutics Inc

PYXSPyxis Oncology Inc

LCTXLineage Cell Therapeutics Inc

Market cap

$248M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.49x

Rev growth (TTM)

-37.1%

YTD performance

-39.4%

52W performance

-42.5%

FCF yield

-10.0%

PYXSPyxis Oncology Inc

Market cap

$168M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-14.2%

YTD performance

76.5%

52W performance

-30.2%

FCF yield

-40.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LCTX

PYXS

Detailed metrics comparison

LCTX

Lineage Cell Therapeutics Inc

PYXS

Pyxis Oncology Inc

Market Cap

LCTX$248M

PYXS$168M

Enterprise Value

LCTX$210M

PYXS$150M

Price

LCTX$0.99

PYXS$2.03

P/E Ratio

LCTXN/A

PYXSN/A

P/S Ratio

LCTX18.94x

PYXS15.26x

EV/Sales

LCTX16.09x

PYXS13.55x

EV/EBITDA

LCTX0.00x

PYXS0.00x

P/B Ratio

LCTX3.86x

PYXS15.60x

P/FCF Ratio

LCTXN/A

PYXSN/A

EV/FCF

LCTX-8.48x

PYXS-2.20x

PEG Ratio

LCTXN/A

PYXSN/A

Forward P/E (NTM)

LCTXN/A

PYXSN/A

Forward P/S (NTM)

LCTX28.49x

PYXSN/A

Revenue (TTM)

LCTX$13M

PYXS$11M

Revenue Growth (YoY)

LCTX-37.1%

PYXS-14.2%

Forward Rev Growth

LCTX-16.6%

PYXS14187.3%

Gross Margin (TTM)

LCTX94.1%

PYXS78.4%

Operating Margin (TTM)

LCTX0.0%

PYXS0.0%

EBITDA Margin (TTM)

LCTX-199.6%

PYXS-580.0%

Net Margin (TTM)

LCTX-246.6%

PYXS-593.0%

FCF Margin (TTM)

LCTX-189.7%

PYXS-615.3%

Net Income (TTM)

LCTX$-32M

PYXS$-65M

FCF (TTM)

LCTX$-25M

PYXS$-68M

EPS (TTM)

LCTX-$0.13

PYXS-$1.03

ROE (TTM)

LCTX-7114.0%

PYXS-10177.0%

ROA (TTM)

LCTX-3087.0%

PYXS-6981.0%

ROIC (TTM)

LCTX-7104.0%

PYXS-10171.0%

Cash

LCTX$37M

PYXS$19M

Debt

LCTX$48K

PYXS$0

Net Cash/Debt

LCTX$37M

PYXS$19M

Current Ratio (TTM)

LCTX6.61x

PYXS1.34x

Quick Ratio (TTM)

LCTX6.44x

PYXS1.25x

Debt/Equity (TTM)

LCTX0.00x

PYXS0.00x

Debt/Assets (TTM)

LCTX0.0%

PYXS0.0%

Interest Coverage (TTM)

LCTXN/A

PYXSN/A

Net Debt/EBITDA (TTM)

LCTX0.00x

PYXS0.00x

Beta

LCTX1.67

PYXS1.37

52W Performance

LCTX-42.5%

PYXS-30.2%

YTD Performance

LCTX-39.4%

PYXS76.5%

% from 52W High

LCTX-52.4%

PYXS-63.4%

% from 52W Low

LCTX12.7%

PYXS97.1%

Asset Turnover (TTM)

LCTX0.07x

PYXS0.00x

FCF Yield (TTM)

LCTX-10.0%

PYXS-40.3%

Earnings Yield (TTM)

LCTX-13.0%

PYXS-38.9%

Dividend Yield (TTM)

LCTXN/A

PYXSN/A

Rule of 40

LCTX-226.8

PYXS-629.5

EV/GP/RG

LCTXN/A

PYXS0.00

Ticker research

View LCTX research View PYXS research

Metric	LCTX Lineage Cell Therapeutics Inc	PYXS Pyxis Oncology Inc
Market & Valuation
Market Cap	$248M	$168M
Enterprise Value	$210M	$150M
Price	$0.99	$2.03
P/E Ratio	N/A	N/A
P/S Ratio	18.94x	15.26x
EV/Sales	16.09x	13.55x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.86x	15.60x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.48x	-2.20x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.49x	N/A
Revenue & Growth
Revenue (TTM)	$13M	$11M
Revenue Growth (YoY)	-37.1%	-14.2%
Forward Rev Growth	-16.6%	14187.3%
Profitability
Gross Margin (TTM)	94.1%	78.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-199.6%	-580.0%
Net Margin (TTM)	-246.6%	-593.0%
FCF Margin (TTM)	-189.7%	-615.3%
Net Income (TTM)	$-32M	$-65M
FCF (TTM)	$-25M	$-68M
EPS (TTM)	-$0.13	-$1.03
ROE (TTM)	-7114.0%	-10177.0%
ROA (TTM)	-3087.0%	-6981.0%
ROIC (TTM)	-7104.0%	-10171.0%
Financial Health
Cash	$37M	$19M
Debt	$48K	$0
Net Cash/Debt	$37M	$19M
Current Ratio (TTM)	6.61x	1.34x
Quick Ratio (TTM)	6.44x	1.25x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.67	1.37
52W Performance	-42.5%	-30.2%
YTD Performance	-39.4%	76.5%
% from 52W High	-52.4%	-63.4%
% from 52W Low	12.7%	97.1%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.00x
FCF Yield (TTM)	-10.0%	-40.3%
Earnings Yield (TTM)	-13.0%	-38.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-226.8	-629.5
EV/GP/RG	N/A	0.00
Ticker research	View LCTX research	View PYXS research

Valuation

P/S Ratio

PYXS

15.26x

LCTX

18.94x

EV/FCF

LCTX

-8.48x

PYXS

-2.20x

Growth & revenue

Revenue Growth TTM

PYXS

-14.2%

LCTX

-37.1%

Forward Revenue Growth

PYXS

14187.3%

LCTX

-16.6%

Profitability & performance

Gross Margin

LCTX

94.1%

PYXS

78.4%

ROE

LCTX

-7114.0%

PYXS

-10177.0%

FCF Yield %

LCTX

-10.0%

PYXS

-40.3%

52-Week Performance

PYXS

-30.2%

LCTX

-42.5%

Detailed metrics comparison

LCTX

Lineage Cell Therapeutics Inc

PYXS

Pyxis Oncology Inc

Market Cap

LCTX$248M

PYXS$168M

Enterprise Value

LCTX$210M

PYXS$150M

Price

LCTX$0.99

PYXS$2.03

P/E Ratio

LCTXN/A

PYXSN/A

P/S Ratio

LCTX18.94x

PYXS15.26x

EV/Sales

LCTX16.09x

PYXS13.55x

EV/EBITDA

LCTX0.00x

PYXS0.00x

P/B Ratio

LCTX3.86x

PYXS15.60x

P/FCF Ratio

LCTXN/A

PYXSN/A

EV/FCF

LCTX-8.48x

PYXS-2.20x

PEG Ratio

LCTXN/A

PYXSN/A

Forward P/E (NTM)

LCTXN/A

PYXSN/A

Forward P/S (NTM)

LCTX28.49x

PYXSN/A

Revenue (TTM)

LCTX$13M

PYXS$11M

Revenue Growth (YoY)

LCTX-37.1%

PYXS-14.2%

Forward Rev Growth

LCTX-16.6%

PYXS14187.3%

Gross Margin (TTM)

LCTX94.1%

PYXS78.4%

Operating Margin (TTM)

LCTX0.0%

PYXS0.0%

EBITDA Margin (TTM)

LCTX-199.6%

PYXS-580.0%

Net Margin (TTM)

LCTX-246.6%

PYXS-593.0%

FCF Margin (TTM)

LCTX-189.7%

PYXS-615.3%

Net Income (TTM)

LCTX$-32M

PYXS$-65M

FCF (TTM)

LCTX$-25M

PYXS$-68M

EPS (TTM)

LCTX-$0.13

PYXS-$1.03

ROE (TTM)

LCTX-7114.0%

PYXS-10177.0%

ROA (TTM)

LCTX-3087.0%

PYXS-6981.0%

ROIC (TTM)

LCTX-7104.0%

PYXS-10171.0%

Cash

LCTX$37M

PYXS$19M

Debt

LCTX$48K

PYXS$0

Net Cash/Debt

LCTX$37M

PYXS$19M

Current Ratio (TTM)

LCTX6.61x

PYXS1.34x

Quick Ratio (TTM)

LCTX6.44x

PYXS1.25x

Debt/Equity (TTM)

LCTX0.00x

PYXS0.00x

Debt/Assets (TTM)

LCTX0.0%

PYXS0.0%

Interest Coverage (TTM)

LCTXN/A

PYXSN/A

Net Debt/EBITDA (TTM)

LCTX0.00x

PYXS0.00x

Beta

LCTX1.67

PYXS1.37

52W Performance

LCTX-42.5%

PYXS-30.2%

YTD Performance

LCTX-39.4%

PYXS76.5%

% from 52W High

LCTX-52.4%

PYXS-63.4%

% from 52W Low

LCTX12.7%

PYXS97.1%

Asset Turnover (TTM)

LCTX0.07x

PYXS0.00x

FCF Yield (TTM)

LCTX-10.0%

PYXS-40.3%

Earnings Yield (TTM)

LCTX-13.0%

PYXS-38.9%

Dividend Yield (TTM)

LCTXN/A

PYXSN/A

Rule of 40

LCTX-226.8

PYXS-629.5

EV/GP/RG

LCTXN/A

PYXS0.00

Ticker research

View LCTX research View PYXS research

Metric	LCTX Lineage Cell Therapeutics Inc	PYXS Pyxis Oncology Inc
Market & Valuation
Market Cap	$248M	$168M
Enterprise Value	$210M	$150M
Price	$0.99	$2.03
P/E Ratio	N/A	N/A
P/S Ratio	18.94x	15.26x
EV/Sales	16.09x	13.55x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.86x	15.60x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.48x	-2.20x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.49x	N/A
Revenue & Growth
Revenue (TTM)	$13M	$11M
Revenue Growth (YoY)	-37.1%	-14.2%
Forward Rev Growth	-16.6%	14187.3%
Profitability
Gross Margin (TTM)	94.1%	78.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-199.6%	-580.0%
Net Margin (TTM)	-246.6%	-593.0%
FCF Margin (TTM)	-189.7%	-615.3%
Net Income (TTM)	$-32M	$-65M
FCF (TTM)	$-25M	$-68M
EPS (TTM)	-$0.13	-$1.03
ROE (TTM)	-7114.0%	-10177.0%
ROA (TTM)	-3087.0%	-6981.0%
ROIC (TTM)	-7104.0%	-10171.0%
Financial Health
Cash	$37M	$19M
Debt	$48K	$0
Net Cash/Debt	$37M	$19M
Current Ratio (TTM)	6.61x	1.34x
Quick Ratio (TTM)	6.44x	1.25x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.67	1.37
52W Performance	-42.5%	-30.2%
YTD Performance	-39.4%	76.5%
% from 52W High	-52.4%	-63.4%
% from 52W Low	12.7%	97.1%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.00x
FCF Yield (TTM)	-10.0%	-40.3%
Earnings Yield (TTM)	-13.0%	-38.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-226.8	-629.5
EV/GP/RG	N/A	0.00
Ticker research	View LCTX research	View PYXS research